Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365293 | 1.00 | HPGD (0.55) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16041868 | 1.00 | HPGD (0.55) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL31045792 | 0.98 | HPGD (0.57) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL18391127 | 0.98 | HPGD (0.57) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL21890138 | 0.98 | HPGD (0.57) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL376485 | 0.95 | MAPT (0.55) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL181567 | 0.95 | MAPT (0.55) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL181566 | 0.95 | MAPT (0.55) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL641221 | 0.94 | MAPT (0.53) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL9104390 | 0.94 | MAPT (0.53) | HPGDMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4051677-B1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECH LTD (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4552639-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST) | Universität Duisburg-Essen (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | NIMBUS IASO, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-18 | — | — | US | disclosed |
| EP-4326716-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-02-28 | — | — | EP | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-2305671-A1 | Thiophene and thiazole derivatives as CHK1 inhibitors | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1732920-A2 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005066163-A2 | THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | XBP1, HSPA5, ERN2 | HPGD 3038/4885MAPT 2402/4885MEN1 4626/4885 |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | HPGD 3165/4885MAPT 3514/4885MEN1 3068/4885 |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | SIGMAR1, TMEM97, OPRD1 | HPGD 1863/4885MAPT 2857/4885MEN1 4564/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | HPGD 95/4885MAPT 3890/4885MEN1 1018/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | HPGD 2082/4885MAPT 2934/4885MEN1 1084/4885 |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | HPGD 808/4885MAPT 2490/4885MEN1 1076/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | HPGD 1838/4885MAPT 1633/4885MEN1 1011/4885 |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | SIK2, SIK1, SIK3 | HPGD 3955/4885MAPT 3781/4885MEN1 3397/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | HPGD 1857/4885MAPT 866/4885MEN1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.